MM is unique biologically and clinically from leukemia and lymphoma.⁶

MM is typically defined as "a clonal plasma cell malignant neoplasm." In reality, it is a collection of several different cytogenetically distinct plasma cell malignant neoplasms.⁷

It is hypothesized that transformation from an MM precursor cell into a malignant one occurs in a multistep process initiated during class switch recombination.⁸

• Normal homeostatic mechanisms fail to prevent the expansion of post-germinal center plasma cells⁹
• Interactions with the bone marrow microenvironment lead to active proliferation of the neoplastic plasma cells^8,9

Dysregulated signaling pathways have been identified that contribute to MM tumor cell growth and survival, immunologic responses in the bone marrow microenvironment, and the development of resistance to therapy.⁹

• In MM pathogenesis, overexpression of pro-survival proteins, BCL-2, BCL-X_L and MCL-1, results in resistance to apoptosis thereby maintaining survival of myeloma cells resulting in their accumulation in the BM^10,11,12

Patients with MM most commonly present with fatigue (due to anemia) or bone pain or fracture at diagnosis.⁷

Tests used to confirm a diagnosis of MM:⁷

• Serum and urinary protein electrophoresis
• Serum immunofixation
• Either a serum free light chain (FLC) assay or 24-hour urinary protein electrophoresis with immunofixation

MM may be morphologically similar, several subtypes of the disease have been identified at the genetic and molecular level, suggesting that diagnosis should include cytogenetics and FISH analyses of bone marrow plasma cells.⁷

In 2014, the IMWG updated the disease definition of MM to include validated biomarkers, referred to as the SLiMCRAB Criteria

Both criteria MUST be met:

• Clonal BM plasma cells ≥10% or biopsy-proven plasmacytoma
• Any one or more of the following myeloma defining events:
  • (≥60%) clonal BM plasma cells (Sixty)
  • Involved/uninvolved serum free Light chain ratio ≥100 (involved FLC level must be ≥100 mg/L)
  • >1 focal lesions on MRI (at least 5 mm in size)
  • Evidence of end-organ damage (CRAB features):
    • HyperCalcemia: >11 mg/dL
    • Renal insufficiency: creatinine clearance <40 mL/min or serum creatinine >2 mg/dL
    • Anemia: hemoglobin <10 g/dL or >2 g/dL below the lower limit of normal
    • Bone lesions: one or more osteolytic lesions

Patients with t(11;14) have traditionally been classified as standard risk MM, based on studies conducted before novel agents were available. Recent observations suggest that patients with t(11;14) may have unfavorable outcomes when compared to other standard risk patients.¹⁴

Treatment for MM includes initial therapy, SCT (if eligible), consolidation/maintenance therapy, and treatment at relapse. Specific therapy and agent(s) utilized are determined by risk, stem cell transplant (SCT) eligibility, and patient fitness and age.²⁵

• Despite recent advances with the advent of proteosome inhibitors (PI), immunomodulatory agents (IMiDs), and monoclonal antibodies, most patients with multiple myeloma (MM) ultimately relapse, and after each relapse, disease becomes more aggressive with shortened subsequent progression free survival (PFS).¹⁶
  • Relapsed/progressive MM acquires additional mutation or genetic alterations that render the disease more resistant, leading to progressively shorter durations of remission or response to each salvage therapy.¹⁷
  • It is estimated that one in eight patients under the age of 65 and one in four patients over the age of 65 in the US will die in the first year after diagnosis of MM.²⁰
  • An international "real world" study showed that approximately 40% of MM patients would not reach a subsequent line of therapy.²⁶
• t(11;14) disease is quite common, occurring in an estimated 15-20% of MM patients.¹⁹
  • When treated with current therapies, t(11;14) patients have shown lower response rates, reduced PFS and OS compared with patients with other traditional standard risk markers.¹⁴

Within the past few years, clinical outcomes of MM have improved due to the introduction of several new agents such as the third-generation immunomodulators (IMiD), next-generation proteasome inhibitors (PIs), anti-CD38 monoclonal antibodies (mAbs), B-cell maturation antigen (BCMA) antibody drug conjugates (ADCs), and BCMA-directed chimeric antigen receptor (CAR) T-cell therapy¹⁶

• However, 5-year survival in the US remains at 55.6%.²²

Despite multiple novel therapeutic options, the optimal combination as well as sequencing of therapy for individual patients remains an important challenge which needs to be addressed. Continued introduction of new agents with non-overlapping mechanisms of action will not only allow for novel multi-agent combinations, but may contribute to continued improvements in outcomes.^18,21

AbbVie is committed to helping address these challenges and is actively conducting research in this area to help address this unmet need.